title: Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate.
abstract: A 39-year-old male underwent distal gastrectomy for a high grade gastrointestinal stromal tumor (GIST). Computed tomography (CT) and magnetic resonance imaging (MRI) 107 mo after the operation, revealed a cystic mass (14 cm in diameter) and a solid mass (9 cm in diameter) in the right and left lobes of the liver, respectively. A biopsy specimen of the solid mass showed a liver metastasis of GIST. The patient received imatinib mesylate (IM) treatment, 400 mg/day orally. Following the IM treatment for a period of 35 mo, the patient underwent partial hepatectomy (S4 + S5). The effect of IM on the metastatic lesions was interpreted as pathologic complete response (CR). Pathologically verified cases showing therapeutic efficacy of IM have been rarely reported.
authors.affiliation: Department of Surgery, Tama-Nagayama Hospital, Nippon Medical School, 1-7-1 Nagayama, Tama, Tokyo 206-8512, Japan. seiji@nms.ac.jp
authors.forename: Seiji
authors.initials: S
authors.lastname: Suzuki
authors.forename: Koji
authors.initials: K
authors.lastname: Sasajima
authors.forename: Masayuki
authors.initials: M
authors.lastname: Miyamoto
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Watanabe
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Maruyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsutani
authors.forename: Aimin
authors.initials: A
authors.lastname: Liu
authors.forename: Masaru
authors.initials: M
authors.lastname: Hosone
authors.forename: Shotaro
authors.initials: S
authors.lastname: Maeda
authors.forename: Takashi
authors.initials: T
authors.lastname: Tajiri
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D017024:Chemotherapy, Adjuvant; D005743:Gastrectomy; D046152:Gastrointestinal Stromal Tumors / Q000473:pathology* / Q000601:surgery; D006498:Hepatectomy; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D008279:Magnetic Resonance Imaging; D008297:Male; D020360:Neoadjuvant Therapy; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate